ISL
NVO

Ingalls & Snyder LLC’s Novo Nordisk NVO Stock Holding History

Ingalls & Snyder LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
28,817
-75
-0.3% -$3.22K 0.04% 202
2026
Q1 		$1.06M Sell
28,892
-586
-2% -$27.8K 0.04% 214
2025
Q4 		$1.5M Sell
29,478
-17,246
-37% -$882K 0.06% 184
2025
Q3 		$2.59M Sell
46,724
-3,957
-8% -$232K 0.08% 144
2025
Q2 		$3.5M Sell
50,681
-1,130
-2% -$76.9K 0.12% 115
2025
Q1 		$3.6M Sell
51,811
-835
-2% -$69K 0.12% 107
2024
Q4 		$4.53M Buy
52,646
+961
+2% +$104K 0.18% 91
2024
Q3 		$6.15M Buy
51,685
+1,037
+2% +$138K 0.24% 75
2024
Q2 		$7.23M Buy
50,648
+19,839
+64% +$2.63M 0.31% 60
2024
Q1 		$3.96M Sell
30,809
-2,355
-7% -$280K 0.17% 97
2023
Q4 		$3.43M Sell
33,164
-1,775
-5% -$176K 0.16% 105
2023
Q3 		$3.18M Buy
34,939
+3
+0% +$264 0.15% 101
2023
Q2 		$2.83M Hold
34,936
– – 0.14% 113
2023
Q1 		$2.78M Hold
34,936
– – 0.14% 105
2022
Q4 		$2.36M Hold
34,936
– – 0.13% 116
2022
Q3 		$1.74M Hold
34,936
– – 0.1% 141
2022
Q2 		$1.95M Hold
34,936
– – 0.1% 139
2022
Q1 		$1.94M Hold
34,936
– – 0.09% 155
2021
Q4 		$1.96M Hold
34,936
– – 0.09% 159
2021
Q3 		$1.68M Sell
34,936
-3,950
-10% -$191K 0.08% 179
2021
Q2 		$1.63M Sell
38,886
-50
-0.1% -$1.94K 0.07% 190
2021
Q1 		$1.31M Hold
38,936
– – 0.06% 205
2020
Q4 		$1.36M Sell
38,936
-2,000
-5% -$69.1K 0.07% 186
2020
Q3 		$1.42M Sell
40,936
-2,200
-5% -$73.3K 0.1% 149
2020
Q2 		$1.41M Sell
43,136
-1,500
-3% -$47.9K 0.08% 164
2020
Q1 		$1.34M Hold
44,636
– – 0.09% 156
2019
Q4 		$1.29M Buy
44,636
+7,130
+19% +$197K 0.07% 173
2019
Q3 		$970K Sell
37,506
-1,006
-3% -$25.4K 0.05% 223
2019
Q2 		$983K Sell
38,512
-9,780
-20% -$242K 0.05% 225
2019
Q1 		$1.26M Sell
48,292
-67,176
-58% -$1.65M 0.06% 193
2018
Q4 		$2.66M Sell
115,468
-58,384
-34% -$1.3M 0.14% 125
2018
Q3 		$4.1M Buy
+173,852
New +$4.24M 0.17% 109

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ingalls & Snyder LLC's NVO Position: Q2 2026 in Review

Ingalls & Snyder LLC reduced its Novo Nordisk (NVO) stake by 0.26% in Q2 2026, selling an estimated $3.22K and leaving 28,817 shares worth $1.38M. The position accounts for 0.04% of the portfolio, ranked #202.

Ingalls & Snyder LLC first reported a position in NVO in Q3 2018 and has held it in 32 quarters since. The position peaked at $7.23M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Ingalls & Snyder LLC held 28,817 shares of Novo Nordisk worth $1.38M as of Q2 2026.
  • Ingalls & Snyder LLC sold 75 Novo Nordisk shares in Q2 2026, an estimated $3.22K.
  • Novo Nordisk made up 0.04% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #202 holding.
  • Ingalls & Snyder LLC first reported a position in Novo Nordisk in Q3 2018 and has held it in 32 quarters since.
  • Ingalls & Snyder LLC's Novo Nordisk position peaked at $7.23M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.